Rappaport Reiches Capital Management, LLC Monopar Therapeutics Transaction History

Rappaport Reiches Capital Management, LLC

  • $376 Billion
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Aug 23, 2023
BUY
$2.05 - $14.95 $21,924 - $159,890
10,695 New
10,695 $25.3 Million

About Monopar Therapeutics

MNPR Quotes by TradingView
  • Ticker MNPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,725,800
  • Market Cap $316M
  • Description
  • Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe ...
More about MNPR
Track This Portfolio

Track Rappaport Reiches Capital Management, LLC Portfolio

Follow Rappaport Reiches Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rappaport Reiches Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rappaport Reiches Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email